Maxim P E, Veltri R W
Cancer. 1986 Jan 15;57(2):305-11. doi: 10.1002/1097-0142(19860115)57:2<305::aid-cncr2820570219>3.0.co;2-d.
A double antibody enzyme immunoassay was used to measure serum ferritin levels in several different control and tumor-bearing populations collected from two institutions. The control groups consisted of normal volunteers, smokers, and Latter Day Saints. No statistically significant differences were noted in ferritin levels between pairs of these groups. Differences were noted among the normal groups when separated on the basis of age and sex, with higher ferritin levels in individuals older than 32 years of age and in men. By one-way analysis of variance, most control groups and subgroups were shown to have significantly lower levels (P less than 0.05) than the head and neck cancer group, with the exception of male smokers, who had levels comparable to male head and neck cancer patients. Serum ferritin levels were higher in head and neck cancer patients than in controls; however, there was no difference when compared with patients with other types of solid malignancies or when considering the anatomic site of the head and neck lesion. Ferritin levels were significantly (P less than 0.05) higher in patients with advanced (Stages III and IV) cancer than in those individuals with Stage I or II cancer. In patients with no evidence of clinical disease 5 years after treatment, the ferritin level had essentially returned to normal. In a group of head and neck cancer patients followed longitudinally, a significant decline in ferritin levels (P less than 0.05) was seen by 5 months after the completion of successful treatment. Furthermore, ferritin levels showed a tendency to increase or remain at high levels in patients with a poor prognosis and to decrease in those patients with a favorable prognosis, giving support to the contention that ferritin may prove to be a valuable tumor marker in head and neck cancer.
采用双抗体酶免疫测定法，对从两个机构收集的多个不同对照组和患癌人群的血清铁蛋白水平进行了测量。对照组包括正常志愿者、吸烟者和后期圣徒。这些组之间的铁蛋白水平未发现有统计学上的显著差异。根据年龄和性别划分正常组时，发现存在差异，32岁以上个体和男性的铁蛋白水平较高。通过单因素方差分析，除男性吸烟者的水平与男性头颈癌患者相当外，大多数对照组和亚组的水平均显著低于头颈癌组（P<0.05）。头颈癌患者的血清铁蛋白水平高于对照组；然而，与其他类型实体恶性肿瘤患者相比或考虑头颈病变的解剖部位时，并无差异。晚期（III期和IV期）癌症患者的铁蛋白水平显著高于I期或II期癌症患者（P<0.05）。治疗后5年无临床疾病证据的患者，其铁蛋白水平基本恢复正常。在一组纵向随访的头颈癌患者中，成功治疗完成后5个月，铁蛋白水平显著下降（P<0.05）。此外，预后不良的患者铁蛋白水平有升高或维持在高水平的趋势，而预后良好的患者铁蛋白水平则下降，这支持了铁蛋白可能被证明是头颈癌中有价值的肿瘤标志物这一观点。
